Ascentage Pharma Group International
AAPG31.730USD
-1.180-3.59%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Ascentage Pharma Group International Company
Ascentage Pharma Group International is a holding company primarily engaged in discovering, developing and commercializing therapies primarily in hematological malignancies. The Company’s main business is engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus and certain age-related diseases. The Company’s main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The Company’s products are mainly used to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. The Company mainly conducts its business in the domestic market.
Ascentage Pharma Group International Info
Ticker SymbolAAPG
Company nameAscentage Pharma Group International
IPO dateOct 28, 2019
CEODr. Dajun Yang, M.D., Ph.D.
Number of employees- -
Security typeDepository Receipt
Fiscal year-end- -
Address68 Xinqing Road, Suzhou Industrial Park
CitySUZHOU
Stock exchangeNASDAQ Global Market Consolidated
CountryChina
Postal code- -
Phone
Websitehttps://www.ascentage.cn/
Ticker SymbolAAPG
IPO dateOct 28, 2019
CEODr. Dajun Yang, M.D., Ph.D.
Company Executives of Ascentage Pharma Group International
Name
Name/Position
Position
Shareholding
Change
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
,
,
Senior Vice President - Global Corporate Development and Finance
Senior Vice President - Global Corporate Development and Finance
--
--
Veet Misra
Veet Misra
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Jin Cao
Mr. Jin Cao
Head - Finance
Head - Finance
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
,
,
Senior Vice President - Global Corporate Development and Finance
Senior Vice President - Global Corporate Development and Finance
--
--
Veet Misra
Veet Misra
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Sep 3
Updated: Wed, Sep 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Point72 (DIFC) Ltd
0.02%
NEOS Investment Management, LLC
0.01%
Tema ETFS LLC
0.01%
HSBC Global Asset Management (UK) Limited
0.01%
Other
99.94%
Shareholders
Shareholders
Proportion
Point72 (DIFC) Ltd
0.02%
NEOS Investment Management, LLC
0.01%
Tema ETFS LLC
0.01%
HSBC Global Asset Management (UK) Limited
0.01%
Other
99.94%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.07%
Investment Advisor/Hedge Fund
0.01%
Other
99.92%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
17
71.71K
0.08%
-198.02K
2025Q2
9
259.43K
0.28%
+259.43K
2025Q1
6
237.19K
0.27%
+237.19K
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Point72 (DIFC) Ltd
20.89K
0.02%
-4.51K
-17.77%
Jun 30, 2025
NEOS Investment Management, LLC
15.49K
0.02%
+15.49K
--
Jun 30, 2025
Tema ETFS LLC
15.49K
0.02%
+15.49K
--
Jun 30, 2025
HSBC Global Asset Management (UK) Limited
9.93K
0.01%
+9.93K
--
Jun 30, 2025
UBS Financial Services, Inc.
7.36K
0.01%
+4.88K
+196.89%
Jun 30, 2025
Chevy Chase Trust Company
5.75K
0.01%
+5.75K
--
Jun 30, 2025
XY Capital Ltd.
5.59K
0.01%
-17.91K
-76.22%
Jun 30, 2025
Morgan Stanley & Co. LLC
956.00
0%
+956.00
--
Jun 30, 2025
Geode Capital Management, L.L.C.
361.00
0%
--
--
Aug 31, 2025
Bell Investment Advisors, Inc.
67.00
0%
+67.00
--
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Tema Oncology ETF
0.51%
Invesco Golden Dragon China ETF
0%
Tema Oncology ETF
Proportion0.51%
Invesco Golden Dragon China ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
